Adverse drug reactions, particularly liver disorders, drive interruptions in anti-tuberculosis treatment: A retrospective cohort study.

ABSTRACT:

Aims

Adverse drug reactions (ADRs) are a key driver of missed doses of anti-tuberculosis (TB) therapy. We aimed to determine the relative burden of ADR-driven missed doses, the missed dose patterns associated with ADRs, and the association between specific ADRs and missed doses.

Methods

In this retrospective cohort study, adults (≥18 years) who began the standard 6-month drug-sensitive anti-TB regimen in an outpatient facility in Riga, Latvia (May 2015-September 2022) and missed at least one dose of treatment were included. Data were collected from medical records and observed therapy records. Missed doses were subdivided into early discontinuation or sporadically missed. Descriptive analyses and lasagne plots were used.

Results

Across 174 patients, 54 (31.0%, CI: 24.

SUBMITTER: Dixon EG 

PROVIDER: S-EPMC12648357 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature